{"nctId":"NCT01505647","briefTitle":"Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)","startDateStruct":{"date":"2012-04"},"conditions":["Herpes Zoster","Shingles"],"count":498,"armGroups":[{"label":"ZOSTAVAX™ (AMP)","type":"EXPERIMENTAL","interventionNames":["Biological: Zoster Vaccine, Live (AMP)"]},{"label":"ZOSTAVAX™","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Zoster Vaccine, Live"]}],"interventions":[{"name":"Zoster Vaccine, Live (AMP)","otherNames":[]},{"name":"Zoster Vaccine, Live","otherNames":["ZOSTAVAX™","V211"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* No fever on day of vaccination\n* History of varicella or residence in a VZV-endemic area for ≥30 years\n* Females of reproductive potential must have a negative pregnancy test and must agree to use acceptable methods of birth control\n\nExclusion Criteria:\n\n* History of hypersensitivity reaction to any vaccine component\n* Prior receipt of any varicella or zoster vaccine\n* Prior history of herpes zoster\n* Have recently had another vaccination\n* Pregnant or breastfeeding\n* Use of immunosuppressive therapy\n* Known or suspected immune dysfunction\n* Concomitant antiviral therapy","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibody","description":"VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"235.7","spread":null},{"groupId":"OG001","value":"208.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"532.6","spread":null},{"groupId":"OG001","value":"457.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers","description":"VZV antibody titers were determined by gpELISA. The GMFR reports the geometric mean of the ratio of individual participant VZV antibody titers at Week 6 / Day 1 (Baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With One or More Adverse Experiences (AEs)","description":"An AE is defined as any unfavorable and unintended change in the\n\nstructure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With One or More Serious Adverse Experience (SAE) Day 1 to 42 Postvaccination","description":"An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \"other important medical event\" based on medical judgement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With One or More Serious Adverse Experience Day 1 to 182 Postvaccination","description":"An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \"other important medical event\" based on medical judgement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":330},"commonTop":["Injection-site pain","Injection-site erythema","Injection-site swelling","Injection-site pruritus"]}}}